Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin GlargineCompleted
NCT03874715Phase 3Updated Apr 17, 2024
Sponsor: Sanofi
Type 1 Diabetes Mellitus
United States
Screening for Gaucher Disease and Acid Sphingomyelinase DeficiencyNot Yet Recruiting
NCT06258577N/AUpdated Apr 15, 2024
Sponsor: Chung-Hsing Wang
Gaucher Disease
Taiwan
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 DiabetesCompleted
NCT05607160N/AUpdated Apr 12, 2024
Sponsor: Sanofi
Type 2 Diabetes Mellitus (T2DM)
Germany
Study of the Effects of Fabrazyme Treatment on Lactation and InfantsTerminated
NCT00230607Phase 4Updated Apr 10, 2024
Sponsor: Genzyme, a Sanofi Company
Fabry Disease · Alpha Galactosidase A Deficiency
United States, Austria, United Kingdom
Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe DiseaseCompleted
NCT02782741Phase 3Updated Apr 4, 2024
Sponsor: Genzyme, a Sanofi Company
Glycogen Storage Disease Type II;Pompe's Disease
United States, Argentina, Australia, Austria, Belgium +20 more
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma PatientsCompleted
NCT02812706Phase 1, Phase 2Updated Apr 1, 2024
Sponsor: Sanofi
Multiple Myeloma
Japan
PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF StudyUnknown
NCT04189029N/AUpdated Mar 28, 2024
Sponsor: Assistance Publique - Hôpitaux de Paris
Heart Failure · Heart Failure With Preserved Ejection Fraction
France
A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy AdultsCompleted
NCT06326814Phase 1Updated Mar 22, 2024
Sponsor: Sanofi
Paroxysmal Nocturnal Hemoglobinuria
United States
Pompe Lactation Sub-RegistryCompleted
NCT00566878N/AUpdated Mar 19, 2024
Sponsor: Genzyme, a Sanofi Company
Glycogen Storage Disease · Pompe Disease
United States
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple MyelomaTerminated
NCT04083898Phase 1Updated Mar 19, 2024
Sponsor: Washington University School of Medicine
Multiple Myeloma
United States
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23Completed
NCT05568979N/AUpdated Mar 13, 2024
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza (Healthy Volunteers)
Finland, Germany
A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in IndiaCompleted
NCT05628090N/AUpdated Mar 8, 2024
Sponsor: Sanofi
Type 2 Diabetes Mellitus (T2DM)
France
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe AsthmaCompleted
NCT05104892Phase 2Updated Mar 7, 2024
Sponsor: Sanofi
Asthma
Argentina, Bulgaria, Canada, Chile, Germany +8 more
Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)Completed
NCT05671770N/AUpdated Mar 6, 2024
Sponsor: Sanofi
Fabry Disease
United Arab Emirates
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous TherapyUnknown
NCT05066607Phase 2Updated Mar 6, 2024
Sponsor: Intergroupe Francophone du Myelome
AL Amyloidosis
France
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Withdrawn
NCT05726682Phase 2Updated Mar 5, 2024
Sponsor: Sanofi
Allogenic Stem Cell Transplantation
Avalglucosidase Alfa Extension StudyCompleted
NCT02032524Phase 2Updated Mar 1, 2024
Sponsor: Genzyme, a Sanofi Company
Glycogen Storage Disease Type II Pompe Disease
United States, Belgium, Denmark, France, Germany +2 more
INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701Withdrawn
NCT05703555Phase 2Updated Feb 28, 2024
Sponsor: Erasmus Medical Center
Metastatic Lung Cancer · Metastatic Breast Cancer · Metastatic Gastric Cancer
Netherlands
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationCompleted
NCT03930732Phase 3Updated Feb 28, 2024
Sponsor: Sanofi
Chronic Obstructive Pulmonary Disease
United States, Argentina, Bulgaria, Canada, Chile +19 more
Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult PatientsCompleted
NCT05409612Phase 3Updated Feb 26, 2024
Sponsor: Assistance Publique - Hôpitaux de Paris
Morbid Obesity · Severe Obesity
France
Plerixafor and Cemiplimab in Metastatic Pancreatic CancerCompleted
NCT04177810Phase 2Updated Feb 23, 2024
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Pancreatic Cancer
United States
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal CancerCompleted
NCT03530267Phase 2Updated Feb 23, 2024
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
Germany
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUMUnknown
NCT06066255Phase 2Updated Feb 20, 2024
Sponsor: Institut Paoli-Calmettes
Hematological Malignancy
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed InfantsTerminated
NCT00418821Phase 4Updated Feb 20, 2024
Sponsor: Genzyme, a Sanofi Company
Mucopolysaccharidosis I · Hurler's Syndrome · Hurler-Scheie Syndrome · Scheie
Italy
My Dose Coach Mobile App to Support Insulin Titration and MaintenanceTerminated
NCT04678661NAUpdated Feb 14, 2024
Sponsor: Linda Siminerio
Diabetes Mellitus Type 2 - Insulin-Treated
United States

Previous page Next page